Innate Pharma Falls After Modest Efficacy Signal in Post-Padcev Bladder Cancer

Innate Pharma stock slides after mixed Phase 1 readout for its Nectin-4 ADC IPH4502. Good tolerability, but efficacy signal in key bladder cancer group remains early and modest.

Innate Pharma Falls After Modest Efficacy Signal in Post-Padcev Bladder Cancer
Credit: Innate Pharma
Already have an account? Sign in.